Australia's most trusted
source of pharma news
Posted 25 June 2026 AM
A promising new prostate cancer treatment developed by Aussie researchers is a step closer to reaching patients after Los Angeles-based Ellison Medical Institute (EMI) acquired rights to the candidate for an undisclosed price.
Based on research led by Professor Greg Monteith from the University of Queensland School of Pharmacy and Pharmaceutical Sciences, QED-203 was developed at the Queensland Emory Drug Discovery Initiative (QEDDI), the small molecular drug discovery group of UniQuest.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.